Global Atypical Teratoid Rhabdoid Tumours Treatment Market Report and Forecast 2023-2031

The global atypical teratoid rhabdoid tumours (ATRT) treatment market is expected to grow at a compound annual growth rate (CAGR) of 7.9% from 2023 to 2031. The increasing incidence of ATRT, the development of novel treatments, and the growing demand for targeted therapies are the primary drivers of the market growth.

Atypical Teratoid Rhabdoid Tumours Treatment Market: Introduction

Atypical teratoid rhabdoid tumours (ATRT) are a rare and aggressive type of brain tumour that typically affects children under the age of three. The tumours are characterized by the loss of a tumour suppressor gene called INI1 or SMARCB1, which is responsible for regulating cell growth. ATRT is often difficult to treat and has a poor prognosis, with a five-year survival rate of less than 20%. The market is dominated by chemotherapy, which is the primary treatment for ATRT. The market is also driven by the development of targeted therapies and immunotherapies, which are designed to specifically target the tumour cells and enhance the immune response against cancer.

Atypical Teratoid Rhabdoid Tumours Epidemiology

ATRT is a rare type of cancer, accounting for less than 1% of all paediatric brain tumours. The incidence of ATRT is highest in children under the age of three, with approximately 60% of cases occurring in this age group. ATRT is more common in boys than girls, with a male-to-female ratio of approximately 1.5:1. The exact cause of ATRT is unknown but there are several risk factors that have been identified. These include genetic syndromes such as the rhabdoid tumour predisposition syndrome, exposure to ionizing radiation, and mutations in the INI1 or SMARCB1 gene.

ATRT is a highly aggressive tumour and has a poor prognosis. The five-year survival rate for children with ATRT is less than 20%. However, recent advances in treatment, including the development of targeted therapies and immunotherapies, have improved outcomes for some patients.

Atypical Teratoid Rhabdoid Tumours Treatment Market Segmentations

The market can be categorised into treatment method, route of administration, treatment channel, and region.

Market Breakup by Treatment Method

• Surgery
• Chemotherapy
• Radiation
• Targeted Immunotherapy
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Market Breakup by Treatment Channel

• Public
• Private

Atypical Teratoid Rhabdoid Tumours Treatment Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Atypical Teratoid Rhabdoid Tumours Treatment Market Scenario

The market is expected to witness significant growth in the coming years, driven by the increasing incidence of ATRT and the development of novel treatments. The market is highly competitive, with several multinational companies and small and medium-sized enterprises operating in the market.

Chemotherapy is the primary treatment for ATRT and dominates the ATRT treatment market. However, the market is also driven by the development of targeted therapies and immunotherapies, which have shown promising results in clinical trials. The increasing demand for personalized medicine and the growing focus on precision oncology are expected to further drive market growth.

North America dominates the ATRT treatment market, accounting for over 50% of the global market share. The high incidence of ATRT in the region, coupled with the presence of a well-established healthcare infrastructure, is driving market growth. Europe is the second-largest market for ATRT treatment, with the increasing adoption of novel therapies and the growing focus on personalized medicine driving market growth.

The Asia Pacific region is expected to witness the highest growth rate during the forecast period, owing to the increasing incidence of ATRT in the region and the rising healthcare expenditure. The growing awareness about ATRT and the availability of new treatment options are also expected to contribute to market growth.

Key Players in the Global Atypical Teratoid Rhabdoid Tumours Treatment Market

The report gives an in-depth analysis of the key players involved in the atypical teratoid rhabdoid tumours treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Takeda Pharmaceutical Company Limited
• Vyriad, Inc
• Novartis AG
• Pfizer Inc
• Ipsen Pharma
• Exelixis, Inc
• Secura Bio
• Istari Oncology Inc